Evercore Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $35
Evercore analyst Vijay Kumar has reiterated a "Buy" rating for Enovis Corp (ENOV.US) but reduced the target price from $40 to $35. TipRanks data indicates that the analyst has a 44.2% success rate and a 0.0% average return over the past year. The information provided is for informational purposes and does not constitute investment advice.
Enovis price target lowered to $35 from $36 at Evercore ISI
Evercore ISI has reduced its price target for Enovis (ENOV) to $35 from $36, while maintaining an Outperform rating on the shares. This adjustment comes as part of the firm's Q1 preview for the medical technology and life science tools sector. The news was first published by TheFly.
Enovis Corporation $ENOV Shares Bought by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC increased its stake in Enovis Corporation (NYSE:ENOV) by 11.6% in the fourth quarter, now owning 757,673 shares valued at approximately $20.09 million. Insiders have also been buying stock, with Oliver Engert purchasing 1,000 shares, bringing insider ownership to 2.70% while institutional investors hold 98.45%. Wall Street analysts have a consensus "Buy" rating for Enovis with an average target price of $47.43, following the company's Q4 earnings beat on EPS but a slight miss on revenue, and its positive FY2026 EPS guidance.
Enovis Corporation (ENOV) stock price, news, quote and history
This article provides a detailed financial overview of Enovis Corporation (ENOV), a medical technology company. It includes current stock price, historical data, performance metrics against the S&P 500, analyst insights, and key financial highlights. The company specializes in developing clinically differentiated solutions across Prevention and Recovery and Reconstructive segments.
Director at Enovis (NYSE: ENOV) receives 770-share stock grant
Enovis director Christine Ortiz received a grant of 770 common shares on March 31, 2026, as a compensation-related award, not an open-market purchase. This transaction increased her direct ownership to 15,665 shares of Enovis common stock. The filing shows no accompanying sales, indicating a routine increase in her equity stake through non-derivative stock compensation.
Enovis Sells Dr. Comfort Business to Promus Equity Partners for Up to $60 Million
Enovis Corporation has completed the sale of its Dr. Comfort diabetic footwear business to Promus Equity Partners for a total consideration of up to $60 million. The transaction involves an initial payment of $40 million, with a potential for an additional $20 million based on Dr. Comfort's future performance. This divestiture is part of Enovis's strategy to streamline its portfolio and focus on its core orthopedic solutions.
Neeraj Chandola to head human resources for India, at Enovis
Enovis, a global medical technology innovator, has appointed Neeraj Chandola as the head of human resources for India. Chandola, previously director HR at RevHC, brings a wealth of experience from various HR roles at companies like Tech Mahindra and AGS Health. In his new role, he is tasked with strengthening HR strategy, driving organizational growth, and enhancing people practices across Enovis's India operations.
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
Several healthcare stocks, including Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health, experienced declines in the afternoon session. This downturn was attributed to increased market uncertainty stemming from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a drop in major indices and consumer confidence. Despite the overall market sentiment, the article suggests that significant price drops can create buying opportunities for high-quality stocks.
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
Several healthcare stocks, including Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health, experienced declines following a broader market downturn. The fall was attributed to investor uncertainty stemming from geopolitical tensions and domestic policy deadlines. Despite the overall market sentiment, the article highlights that such dips can present buying opportunities for high-quality stocks.
Press Release: Enovis Announces First Quarter 2025 Results
The article, published by Dow Jones, announces Enovis's first-quarter 2025 results. It highlights Unity Software's fourth-quarter financial results which showed a 35% year-over-year revenue increase to $609 million, surpassing the consensus estimate. However, Unity also reported a quarterly loss of 66 cents per share.
[SCHEDULE 13G/A] Enovis CORP Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for Enovis Corp (ENOV), reporting 0 shares beneficially owned, representing 0% of Common Stock. This amendment is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing states that The Vanguard Group no longer has beneficial ownership over securities held by these disaggregated subsidiaries.
Enovis Delivers 7% Sales Growth in Q2, Raises Full-Year Outlook
Enovis announced robust 7% sales growth in Q2 2024, excluding a 150 basis point impact from foreign exchange, and has subsequently raised its full-year outlook. The company's strong performance was driven by significant growth in both its MedTech segments, particularly in Reconstructive and P&R businesses, and a substantial increase in diluted EPS. This positive momentum indicates a strong financial health and promising future for Enovis.
Enovis Delivers 7% Sales Growth in Q2, Raises Full-Year Outlook
Enovis announced strong Q2 financial results, achieving 7% sales growth driven by robust performance in its Reconstructive and P&R segments. The company's adjusted EPS increased by 19%, and it has raised its full-year revenue and adjusted EPS guidance, signaling confidence in continued growth. These results highlight Enovis's successful execution of its strategic initiatives and market demand for its medical technology solutions.
DAVENPORT & Co LLC Cuts Stock Holdings in Enovis Corporation $ENOV
DAVENPORT & Co LLC reduced its stake in Enovis Corporation (NYSE:ENOV) by 13.1% in the fourth quarter, selling 367,689 shares and now owning 2,439,308 shares valued at $64.98 million. Despite this, other hedge funds increased their positions, and insiders recently purchased shares. Analysts generally maintain a "Buy" rating for Enovis with an average price target of $47.43, and the company recently exceeded EPS estimates while providing strong FY2026 guidance.
Wall Street experts predict Enovis (ENOV) could climb by 100.71%: Is such a surge truly possible for the stock?
Wall Street analysts predict Enovis (ENOV) could see a 100.7% increase, with an average price target of $45.18. While analyst price targets can be unreliable and potentially biased, a low standard deviation in these targets suggests a strong consensus among experts. ENOV's recent upward trend in earnings estimates and a Zacks Rank #1 (Strong Buy) also indicate potential for further upside.
Wall Street experts predict Enovis (ENOV) could climb by 100.71%: Is such a surge truly possible for the stock?
Wall Street analysts project a potential 100.7% surge for Enovis (ENOV) stock, with an average price target of $45.18. Despite the variability in individual forecasts, a low standard deviation indicates a strong consensus among experts. The stock also shows encouraging signs for investors, including recent upward trends in earnings estimates and a Zacks Rank #1 (Strong Buy) rating.
Enovis Corporation (NYSE:ENOV) Receives Average Recommendation of "Buy" from Analysts
Enovis Corporation (NYSE:ENOV) has received an average "Buy" recommendation from nine analysts, with a collective 12-month price target of $47.43. This positive outlook is further supported by recent insider purchases, including a director buying 1,000 shares, indicating strong insider confidence. The company also surpassed EPS estimates in its latest quarterly report and provided optimistic FY2026 guidance.
Enovis Corporation (NYSE:ENOV) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for Enovis Corporation (NYSE:ENOV). It contains the spoken words from company executives and analysts during the conference call discussing the company's financial results and outlook.
Wells Fargo Sticks to Its Buy Rating for Enovis (ENOV)
Wells Fargo analyst Larry Biegelsen reiterated a Buy rating on Enovis (ENOV) with a price target of $42.00, while the stock closed at $23.46. The company recently reported Q4 revenue of $575.76 million. Corporate insider sentiment for ENOV is positive, with an increase in insider buying, including CAO Oliver Engert purchasing 1,000 shares.
Enovis (NYSE:ENOV) Rating Increased to Strong-Buy at Wells Fargo & Company
Wells Fargo & Company upgraded Enovis (NYSE:ENOV) to a "strong-buy" rating, contributing to a consensus "Buy" rating with an average price target of $47.43. The company recently reported better-than-expected EPS of $0.95 and provided strong FY2026 guidance, despite missing revenue estimates. Insiders and institutional investors have shown confidence in Enovis, with significant insider stock purchases and 98.45% institutional ownership.
UBS reiterates Enovis stock Buy rating on growth outlook
UBS has reiterated a Buy rating and a $50.00 price target on Enovis Corp (NYSE:ENOV) shares, citing strong fundamentals and growth outlook. The firm anticipates mid-single-digit percentage growth, margin expansion, and improved cash generation for Enovis, with expectations for the company to meet or exceed guidance for 2026. This positive outlook is supported by recent earnings performance and analyst revisions.
Enovis (ENOV) to report earnings tomorrow: Here is what to expect
This article provides an earnings preview for Enovis (ENOV) ahead of its report tomorrow. It includes consensus estimates for EPS and revenue, reflecting a potential year-over-year improvement. The piece also details what factors investors should focus on, such as revenue growth, margins, research and development spending, and the company's outlook.
Wells Fargo Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $42
Wells Fargo analyst Larry Biegelsen has reiterated a buy rating for Enovis Corp (ENOV.US) but has significantly reduced the target price from $73 to $42. Biegelsen's rating is based on TipRanks data, reflecting a 47.1% success rate and a 0.4% average return over the past year. The provided information is for informational purposes only and not an investment recommendation.
[Form 4] Enovis CORP Insider Trading Activity
Enovis Corp's Chief Administrative Officer, Oliver Engert, purchased 1,000 shares of company common stock at $23.74 per share on March 13, 2026, increasing his direct ownership to 48,640 shares. This open-market transaction was reported as a neutral impact with positive sentiment in the Form 4 SEC filing. The filing provides transparent details of the insider buying activity, confirming an increased equity stake for the officer.
Enovis tops profit expectations but revenue falls short
Enovis exceeded its profit expectations, but its revenue did not meet forecasts. This indicates a mixed financial performance for the company, with stronger cost management or higher-margin sales driving profits despite overall lower revenue than anticipated.
Engert Oliver, chief administrative officer, buys Enovis Corp (ENOV) shares By Investing.com
Enovis Corp's Chief Administrative Officer, Oliver Engert, purchased 1,000 shares of the company's stock for $23.74 per share, totaling $23,740. This transaction increases his direct ownership to 48,640 shares, occurring while the stock is significantly below its 52-week high, and is considered undervalued according to InvestingPro. The purchase follows the company's Q4 2025 earnings report, which showed higher-than-expected EPS but slightly lower revenue, and an increased price target from Needham.
Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock
Enovis insider Oliver Engert recently purchased 1,000 shares of the company's stock at $23.74 per share, bringing his direct ownership to 48,640 shares. This is part of a series of six purchases totaling 5,000 shares since February 27th. Enovis (NYSE:ENOV) reported strong earnings, beating estimates, and has a "Moderate Buy" average analyst rating with a target price significantly above its current trading price, despite a negative net margin.
Engert Oliver, chief administrative officer, buys Enovis Corp (ENOV) shares
Oliver Engert, Chief Administrative Officer of Enovis Corp (ENOV), purchased 1,000 shares of company stock for $23,740 on March 13, 2026. This insider buying occurs while the stock is trading significantly below its 52-week high, with some analysts suggesting it is undervalued. The company recently reported strong Q4 2025 EPS, exceeding forecasts, and provided positive guidance for 2026 EPS, leading Needham to raise its price target to $52.
Invenomic Capital Management LP Has $21.62 Million Holdings in Enovis Corporation $ENOV
Invenomic Capital Management LP significantly increased its stake in Enovis Corporation, buying an additional 131,705 shares to reach a total holding of 712,669 shares valued at $21.62 million. This move makes Enovis the fund's 28th largest holding, representing 1.0% of its investment portfolio and 1.25% of Enovis. The medical technology company, Enovis, recently reported better-than-expected Q3 EPS of $0.95 and provided positive FY2026 guidance, while analysts maintain a "Moderate Buy" rating with an average price target of $47.43.
Enovis (ENOV) CAO Oliver Engert buys 1,000 shares in open-market trade
Enovis CORP's Chief Administrative Officer, Oliver Engert, bought 1,000 shares of common stock in an open-market purchase at a weighted average price of $23.93 per share. This transaction increases his direct ownership to 47,640 common shares and was executed through multiple trades ranging from $23.75 to $24.10 per share. The purchase is noted as a routine increase in personal investment exposure.
Engert Oliver, chief administrative officer at Enovis, buys $23,930 in ENOV
Engert Oliver, the chief administrative officer at Enovis (NYSE:ENOV), recently purchased 1,000 shares of the company's common stock for $23,930. This insider transaction follows a period where the stock has declined 12% year-to-date, though analysis indicates it may be undervalued. The purchase aligns with positive analyst sentiment, and Enovis recently reported strong Q4 2025 earnings per share, with Needham raising its price target for the company.
ENOV SEC Filings - Enovis Corp 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Enovis Corp (ENOV) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Stock Titan offers AI-powered summaries to help users quickly understand the significance of these regulatory disclosures. Recent filings cover executive stock transactions, goodwill write-downs, 2025 financial results showing sales growth but a net loss due to impairment, and institutional ownership disclosures.
Barclays PLC Lowers Stake in Enovis Corporation $ENOV
Barclays PLC significantly reduced its holdings in Enovis Corporation, selling over 381,000 shares, which now represents 1.23% of the company. Despite this, other major institutional investors like Vanguard Group Inc. and Dimensional Fund Advisors LP increased their stakes in Enovis. The article also covers Enovis's recent financial performance, analyst ratings, and an insider stock purchase.
Enovis (ENOV) legal chief receives 25,586-share award and tax withholding
Enovis's SVP and Chief Legal Officer, Tandy Bradley J, was granted 25,586 shares of common stock as a compensation award on March 9, 2026. Prior to this, on March 7, 2026, 1,874 shares were withheld by the company at $24.51 per share to cover tax obligations related to restricted stock units. Following these transactions, Bradley directly holds 65,641 shares of Enovis common stock.
Enovis (ENOV) Is Down 5.5% After 2025 Loss And 2026 Revenue Outlook Update - Has The Bull Case Changed?
Enovis (ENOV) recently reported its Q4 and full-year 2025 results, showing sales of US$575.76 million and US$2.25 billion respectively, but also a significant net loss of US$1.18 billion due to a US$501.31 million goodwill impairment. For 2026, the company projects revenue between US$2.31 billion and US$2.37 billion, indicating 4-6% organic growth. This outlook suggests continued top-line growth for Enovis, despite ongoing challenges with integration and impairment charges from past acquisitions impacting profitability.
Enovis (ENOV) Is Down 5.5% After 2025 Loss And 2026 Revenue Outlook Update - Has The Bull Case Changed?
Enovis (ENOV) reported a significant 2025 net loss of US$1.18 billion due to a large goodwill impairment charge, despite sales of US$2.25 billion. The company issued 2026 revenue guidance expecting US$2.31 billion to US$2.37 billion, representing 4–6% organic growth. This update raises questions about the company's investment narrative, emphasizing the importance of consistent organic growth in orthopedics while highlighting ongoing concerns related to past acquisitions and impairment issues.
Enovis (ENOV) grants 14,925 RSUs to its principal accounting officer
Enovis Corp.'s principal accounting officer, John Kleckner, was granted 14,925 restricted stock units (RSUs) on March 9, 2026. These RSUs, awarded at no cost, will vest in three equal annual installments beginning one year from the grant date. Additionally, 586 shares were withheld on March 7, 2026, at $24.51 per share to cover tax obligations related to a prior RSU net settlement, which the company clarified is not a sale by Kleckner. Following these transactions, Kleckner directly holds 25,884 common shares.
Enovis (ENOV) Is Down 5.5% After 2025 Loss And 2026 Revenue Outlook Update - Has The Bull Case Changed?
Enovis Corporation (ENOV) reported a significant net loss of US$1.18 billion for fiscal year 2025, primarily due to a US$501.31 million goodwill impairment charge, despite overall sales growth. The company provided 2026 revenue guidance between US$2.31 billion and US$2.37 billion, indicating 4-6% organic growth. This update aims to assess how the new financial results and guidance might impact Enovis's investment outlook, particularly regarding its ability to achieve sustainable profitability from its orthopedic portfolio.
Enovis (ENOV) CEO receives 143,923-share RSU grant, total 246,676 held
Enovis Corp's CEO, Damien McDonald, was granted 143,923 restricted stock units (RSUs) as an equity award, which will vest in three equal annual installments starting on the first anniversary of the grant date. This grant increases his direct holdings to 246,676 shares of Enovis common stock. The transaction, reported in a Form 4 SEC filing, is characterized as a compensation-related grant rather than an open-market purchase.
Enovis (ENOV) CFO awarded 47,974 RSUs as 3,167 shares withheld for taxes
Enovis Corp's CFO, Phillip Benjamin (Ben) Berry, received an equity grant of 47,974 Restricted Stock Units (RSUs) that will vest in three equal annual installments. Separately, 3,167 shares were withheld by the company at $24.51 per share to cover tax obligations related to the net settlement of RSUs, which the company clarified was not a sale by Berry. Following these transactions, Berry directly holds 158,596 shares of Enovis common stock.
Enovis (NYSE:ENOV) Insider Oliver Engert Purchases 750 Shares
Oliver Engert, an insider at Enovis (NYSE:ENOV), recently purchased 750 shares of the company's stock for $24.41 per share, increasing his total ownership to 45,640 shares valued at over $1.11 million. This transaction is part of a larger series of purchases by Engert in late February and early March. The company recently reported Q4 EPS above estimates but slightly missed revenue, and analysts maintain a mostly bullish outlook with a consensus price target of $47.43.
Insider Buying: Oliver Engert Acquires Shares of Enovis Corp (ENOV)
Oliver Engert, Chief Administrative Officer at Enovis Corp, purchased 1,750 shares of the company on March 9, 2026, increasing his total holdings to 46,640 shares. This transaction is part of a trend of insider buying at Enovis, with 8 purchases and 1 sale over the past year. Despite the insider purchases, Enovis Corp's stock is currently trading at $23.83, below its estimated GF Value of $52.85, suggesting it might be a "Possible Value Trap."
Unveiling Q4 Financial Results: How Enovis (NYSE:ENOV) Compares With Other Specialty Medical Devices & Supplies Stocks
This article analyzes the Q4 performance of several specialty medical device and supply companies, focusing on Enovis (NYSE:ENOV) and comparing its results with top and bottom performers like Globus Medical (NYSE:GMED) and STAAR Surgical (NASDAQ:STAA). It highlights the mixed financial outcomes across the sector, discusses industry trends, and touches on the broader market outlook. The report offers a snapshot of revenues, analyst expectations, and stock movements for each company mentioned.
Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock
Enovis insider Oliver Engert recently purchased 1,000 shares of the company's stock at $23.39 per share, increasing his direct stake to 46,640 shares. This transaction follows several other purchases in late February and early March. The company's stock traded down 3.2% to $23.87, and Enovis reported beating EPS estimates for its last quarter while revenue slightly missed consensus.
Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
This article analyzes the Q4 earnings of Enovis (NYSE:ENOV) and other specialty medical devices and supplies companies, highlighting mixed results across the sector. Enovis reported a revenue miss but an EPS beat, with its stock performing positively post-earnings. The article also details the best performer, Globus Medical (NYSE:GMED), and the weakest, STAAR Surgical (NASDAQ:STAA), while providing an overall market update on the sector.
A Look At Enovis (ENOV) Valuation After 2025 Earnings Losses And 2026 Revenue Guidance
Enovis (ENOV) is back in focus after reporting Q4 and full-year 2025 results, which included continued net losses, significant goodwill impairment charges, and new 2026 revenue guidance. Despite weak longer-term momentum and ongoing losses, Enovis is considered 45.6% undervalued by the market, with a fair value of $45.09 against its current price of $24.51, based on expectations of future revenue growth, margin reset, and stronger free cash flow. Investors are assessing whether the current market valuation aggressively discounts future growth or accurately reflects the risks associated with the company's financial performance.
Enovis Outperforms Rennova Health in Key Financial Metrics
Enovis and Rennova Health are both small-cap medical companies, but an analysis of their financial performance and other key metrics shows that Enovis is the stronger business overall. Enovis has lower volatility, higher profitability, and greater institutional ownership compared to Rennova Health. This comparison highlights the financial health and growth potential of these two medical companies, which can be important information for investors and industry observers tracking the performance of small-cap players in the healthcare sector.
Zacks Research Upgrades Enovis (NYSE:ENOV) to Strong-Buy
Zacks Research has upgraded Enovis (NYSE:ENOV) from a "hold" to a "strong-buy" rating, contributing to an overall "Moderate Buy" consensus from analysts with a target price of $47.43. The company recently reported Q earnings per share of $0.95, beating expectations, but revenue slightly missed forecasts. Enovis's stock opened at $24.29, and institutional investors hold a significant 98.45% of its shares.
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
Wall Street analysts project Enovis (ENOV) could see a 76.6% surge, with a mean price target of $45.55 based on 11 short-term estimates. The company's stock has already gained 13.1% in the past four weeks, closing at $25.79. Despite the potential for misleading price targets, a positive trend in earnings estimate revisions and a Zacks Rank #1 (Strong Buy) reinforce the bullish outlook.
Insider Buying: Enovis (NYSE:ENOV) Insider Buys 1,000 Shares of Stock
Enovis (NYSE:ENOV) insider Oliver Engert recently purchased 1,000 shares of the company's stock, adding to earlier purchases in late February and early March. These transactions increased his total holdings by 2.29% to 44,640 shares. The medical technology company reported strong Q4 EPS, beating estimates, and analysts maintain a "Moderate Buy" rating with an average price target significantly above the current trading price.
